Single-Analyte vs Combo Respiratory Rapid Tests: A Buyer's Guide

Respiratory rapid tests are available as single-analyte products (detecting one target, such as influenza A/B or RSV) or as combination products (detecting multiple targets on a single device, such as Flu A/B plus RSV, or Flu/RSV/COVID-19). For distributors, the choice involves clinical need, workflow efficiency, inventory management, regulatory requirements and total cost.

When single-analyte products fit

Single-analyte tests may be appropriate when clinical demand is concentrated on one target, when testing protocols call for sequential rather than simultaneous testing, or when a single SKU offers better economics at scale. For example, a hospital laboratory may prefer a high-volume influenza A/B-only test for seasonal screening, with RSV tested separately only for specific patient populations.

Single-analyte products may also simplify regulatory approval and marketing, since each product has a narrower intended use and evidence scope. Distributors can build a modular portfolio by carrying separate influenza, RSV and other respiratory products.

When combination products fit

Combination tests are useful when multiple respiratory pathogens must be ruled out from the same clinical encounter, reducing the number of swabs, devices and processing steps. A Flu/RSV combo test, for example, can differentiate both infections from a single sample in one workflow.

Combination products may also be attractive for point-of-care settings, urgent care clinics, pharmacies or home-testing scenarios where convenience and speed matter. However, distributors should verify that the combination product has separate performance data for each target and that the intended-use claims match the clinical scenario.

Commercial comparison

From a commercial standpoint, single-analyte tests may have lower per-test cost but require managing multiple SKUs, separate inventory levels and potentially different expiry dates. Combination tests may have higher per-test cost but reduce SKU complexity and offer a bundled value proposition to end users.

Distributors should compare total cost per patient encounter, not just per-test price. If a combination test eliminates the need for a second swab and device, the combined cost may be lower or comparable to running two single-analyte tests.

Technical and regulatory comparison

Each target on a combination test must have its own performance data and regulatory clearance. A combo product is not simply a physical combination of two single tests; it may have different sensitivity, specificity and cross-reactivity characteristics. Distributors should request product-specific documentation for each analyte.

EU buyers should consider IVDR classification and conformity requirements; other markets may have separate local registration pathways. Combination products may have higher regulatory complexity if each target is classified differently or if the combination configuration requires additional evidence.

Portfolio strategy

A balanced portfolio may include both single-analyte and combination products. Single-analyte tests can serve high-volume, cost-sensitive channels, while combination tests can serve clinics, pharmacies and settings where differential diagnosis is valued. The right mix depends on local clinical guidelines, competitive landscape and channel preferences.

PRISES offers both single-analyte and combination respiratory test configurations. Distributors should discuss target configurations, evidence availability and destination-market requirements before finalizing product selection.